Intended for healthcare professionals
HIDRADENITIS SUPPURATIVA

Hidradenitis suppurativa – Part 2

Dr Hannah Wainman

MBBS MRCGP
Locum Consultant Dermatologist Gloucestershire Hospitals NHS Foundation Trust

Dr Emily Davies

BMBS MRCP Consultant Dermatologist
Gloucestershire Hospitals NHS Foundation Trust

Part one of this series covered the epidemiology, pathophysiology, risk factors, clinical features and investigations in hidradenitis suppurativa (HS). In the second part of this series, we will cover pharmacological treatment options for HS. Our final part of this three-part series will focus on dressings and surgical options.

Dermatology in practice 2022; 28(4): 84–86
To continue reading this article, please sign in or register.

Dermatology in practice was previously supported by Wyeth from 2008 to 2010, by Wyeth and Serono in 2007, by Wyeth and Shire from 2005 to 2006, by Medlock Medical in 2004 and by SSL International from 2001 to 2003.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the publisher, Editor or Editorial Board. Accordingly the publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Dermatology in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 0262-5504 (Print) ISSN 2049-8446 (Online)